ページ3 - 最高の医師 - トップ150名の医師

セヴリーヌ・イボラ医師は、ゾーリンゲン市立病院の産婦人科部門を率い、低侵襲治療および腫瘍学的治療を専門としています。

• 婦人科腫瘍学および特殊産科の認定資格取得
• 泌尿器婦人科学および骨盤底再建手術の専門家
• ドイツ主要医学会の現役会員
• 腹腔鏡手術およびダ・ヴィンチ・ロボットシステムを用いた術式を実施

Dr. Marc Ulrich Becher is an interventional cardiologist and heart failure specialist at Städtisches Klinikum Solingen. He is known for performing advanced procedures such as coronary angiography, radiofrequency ablation with 3D mapping, carotid angioplasty, and stenting.

Dr. Becher’s clinic carries out about 3,000 to 4,000 diagnostic and therapeutic procedures each year. These include complex coronary interventions, catheter-based valve replacements, and structural heart procedures. He is experienced in using advanced imaging techniques like IVUS and OCT for accurate diagnosis and treatment planning.

Dr. Becher is dedicated to providing thorough and compassionate care. He uses modern therapies for both acute and chronic cardiovascular diseases, focusing on patient safety and positive outcomes.

EDUCATION

• Graduated in General Medicine at Universidad Autónoma de Nayarit in Mexico
•  
• Training in Forensic Medicine at Jalisco Institute of Forensic Sciences in Mexico
•  
• Training in Regenerative Geriatric Medicine at Nordic University
•  
• Master’s Degree in Regenerative Medicine at Universidad Catolica de Murcia in Madrid, Spain
•  
• Training in Regenerative Medicine at Nordic University

EXPERIENCE

• Founder of the biotechnological institute “Bioplenum S.A de C.V”
•  
• Collaborated in clinical protocols in Lyon, France, with Dr. Lourdes Sagnard
•  
• Clinical researcher in many protocols involving mesenchymal stem cells to treat autoimmune and chronic degenerative diseases, including: diabetes, asthma, ischemic events, ALS (Lou Gehrig’s disease), arthritis, kidney failure, lupus, aesthetic facial regeneration, and as an anti-inflammatory and immunomodulatory agent

ACCOLADES

• HemoFenix France representative in Mexico and Latin America
•  
• Kimicor Pharma representative at the Italian laboratory in Mexico
•  
• Krebs International, General Director for the company located in Bulgaria
•  
• General Director for Immunotherapy for México A.C. foundation

ヴィクトール・アレクサンダー・クロル医師は、デュッセルドルフのザンクト・マルティヌス病院において消化器内科および内科部門を統括し、肥満および代謝疾患の高度治療を専門としています。

• 外科的および内視鏡的治療を備える認定肥満治療センターのディレクター
• 肥満外科手術および内視鏡的減量技術の専門家
• 消化器疾患、心血管疾患、呼吸器疾患への包括的アプローチ
• 最新の診断・治療法を駆使した最適な患者アウトカムの実現

Education and Expertise

Medical Education: Istanbul University, Cerrahpaşa Faculty of Medicine (1995)

Specialization: Anesthesia and Reanimation, S.B. Haydarpaşa Numune Training and Research Hospital (2000 to 2005)

Master's Degree: İstinye University, Institute of Social Sciences, Health Management (2020 to 2022)

PhD: İstinye University, Faculty of Graduate Education, Health Management (2022 to Present)

Experience

1997 to 1999 – General Practitioner, Private Marmara Hospital (Maltepe University), Cardiology Department

2005 to Present – Anesthesiology and Reanimation Clinic, S.B. Haydarpaşa Numune Training and Research Hospital

2005 to 2006 – Responsible Physician of Anesthesia and Intensive Care, Grup Universal Hospital, Kadıköy

2006 to 2012 – General Intensive Care Responsible Physician, Group Florence Nightingale Hospitals, Şişli

2012 to 2017 – General Intensive Care Responsible Physician, Grup Memorial Service Hospital

2017 to 2018 – General Intensive Care Unit, VM Medical Park Hospital, Kocaeli

2018 to Present – Responsible Manager, General Intensive Care Unit, VM Medical Park Hospital, Pendik

Professional Memberships

-Turkish Medical Association

-Turkish Anesthesiology and Reanimation Association

-Turkish Intensive Care Association

-Turkish Neurology Association

-Skull Base Association

マーカス・デュークス教授は、診断放射線学と低侵襲治療の専門家です。

受賞歴

• 大阪医科大学（日本）の名誉教授金メダル。
• DeGIR（ドイツ介入放射線学および低侵襲治療学会）の名誉会員。

学歴と職歴

• 1982-1988 - マインツのヨハネス・グーテンベルク大学で医学を学ぶ。
• 1988 - 医学ライセンスの取得。
• 1988-1989 - ドイツ連邦軍の医療将校。
• 1990 - マインツのヨハネス・グーテンベルク大学で、放射線学分野における医学博士、論文: 「バルーン拡張中の速度が成功に与える影響及び血管壁への損傷についての研究」。
• 1990-1996 - ルプレヒト・カール大学の放射線学部のレジデント。
• 1996 - ハイデルベルクのルプレヒト・カール大学の放射線診断学部の上級医師。
• 1998 - 診断放射線学の博士号取得、論文: 「胃癌のイメージング手法の直接比較：臨床現場での最適化された検査法の重要性とMRIによる初経験」。
• 2000 - ハイデルベルクのルプレヒト・カール大学放射線診断学部の副部長。
• 2000-2002 - ハイデルベルク大学の整形外科クリニックの画像処理センター長。
• 2002-2003 - ハイデルベルクのルプレヒト・カール大学の外科クリニック、放射線学部の部長。
• 2003 - フランクフルトのノルトウエスト・クリニックの中央放射線・神経放射線学研究所のチーフ・フィジシャン。
• 2006 - ハイデルベルク大学放射線学部の准教授。

科学活動

マーカス・デュークスは、CTガイド下での肝臓および肺腫瘍の低侵襲マイクロ波焼灼を実施した最初の医師の一人です。

臨床活動

教授は、ライン＝マイン地域で唯一のMRIガイド下のFUS焼灼センターを主導しています。多くの場合、この手法は外科的介入を回避することができます。センターの患者は、前立腺癌、骨および肝臓の転移、良性腫瘍、および非手術による子宮筋腫の焼灼の治療を受けることができます。

所属団体

• DRG（ドイツ放射線学会）。
• DeGIR（ドイツ介入放射線学および低侵襲治療学会）。
• RSNA（北米放射線学会）。
• ESGAR（ヨーロッパ消化器および腹部放射線学会）。
• CIRSE（欧州循環器・介入放射線学会）。
• ECR（ヨーロッパ放射線学会議）。
• EUFUS（ヨーロッパFUS学会）。
• MEDICA（ドイツ学際医学会）。

Through rigorous training and practical experience, they have developed a deep understanding of Urology, earning recognition for their diagnostic skills and effective treatment approaches. Dr. Ahmet Tevfik Albayrak is a distinguished member of the European Society for Sexual Medicine (ESSM), a testament to their expertise and dedication in the field of sexual health. As a member of the ESSM, Dr. Ahmet Tevfik Albayrak remains connected to a network of professionals dedicated to advancing the field of sexual medicine. Their contributions to research, education, and clinical practice have earned them recognition from their peers and gratitude from the patients they serve. Furthermore, through their involvement with the ESSM, Dr. Ahmet Tevfik Albayrak stays abreast of the latest developments in sexual medicine, ensuring that they are equipped with the knowledge and skills needed to provide the highest quality of care to their patients. Their commitment to excellence and their compassionate approach to patient care continue to make a meaningful impact on the field of sexual health.

Assoc. Prof. Dr. Özlem Köroğlu is a specialist in Physical Medicine and Rehabilitation at Memorial Ankara Hospital (2024–present). She previously served as a faculty member at Gaziler Physical Therapy and Rehabilitation Training and Research Hospital (2016–2024). She was Chief of the Physical Medicine and Rehabilitation Clinic at Elazığ Military Hospital (2011–2015). She earned her MD in 2003 from the GATA Faculty of Medicine. She completed her PM&R residency in 2011.

Her credentials include Ministry of Health–approved certified prolotherapy training. She has taught Prolotherapy and PRP (2022) and Knee Prolotherapy and Campinject (2019). She also taught GETAT and Dextrose Prolotherapy (2018) and ISPRM Ultrasound (2009). She has additional training in musculoskeletal ultrasound, neural therapy, lumbar injections and manipulation, and botulinum toxin treatment for the spastic hand. She attended the Euro‑Mediterranean PRM School in Italy (2010). She is a member of the Turkish Society of PM&R, the Turkish Society for Research and Fight Against Rheumatism, the Association of PM&R Specialists of Türkiye, the Spinal Cord Diseases Association, and the Ankara Medical Chamber.

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

Dr. Boaz Liberman, MD, is an orthopedic oncologist and sarcoma surgeon for adults and children. He directs the Orthopedic Oncology Unit and serves as Vice Head of Orthopedic Surgery at Sheba Medical Center. His focus is limb-sparing cancer surgery with functional reconstruction. He performs complex joint reconstruction, revision arthroplasty, MRgFUS, and reconstruction after bone metastases.

Education and training: MD, Tel Aviv University. Orthopedic surgery residency, Sheba Medical Center. Fellowships in Adult Reconstruction at Mount Sinai Hospital, Toronto, and in Orthopedic Oncology at Mount Sinai Hospital and Princess Margaret Cancer Centre. He is board-certified in Orthopedic Surgery and in Orthopedic Oncology Surgery. He is a Clinical Instructor at Tel Aviv University. Memberships include the Israel Medical Association, Israel Orthopedic Association, AATB, and EATB. He also serves on national advisory committees. His research covers bone and soft tissue sarcomas, serum markers, imaging-guided therapies, MRI arthrography, and the biomechanics of bone treated with MRgFUS.

Rawipa Khunnarong, M.D. (Dr. Praew), is a physiatrist at Police General Hospital, Bangkok (2025–present). She provides rehabilitation for musculoskeletal pain, neurological disorders, and functional impairments. She works with multidisciplinary teams and teaches and supervises residents.

Education: M.D., Rangsit University/Rajavithi Hospital (2019). Rehabilitation Medicine Residency, Phramongkutklao College of Medicine (2025). Core expertise includes pain and interventional rehabilitation, neurorehabilitation (stroke, spinal cord injury), dysphagia, and sports and exercise medicine.

Advanced training includes Sports Rehabilitation Beyond Strength (2025), PMK Dry Needling (2025), and the 3rd Musculoskeletal Intervention Course (2025). She also completed a BASEM study visit (2024), Olympus FEES for dysphagia (2024), AOCNR (2023), TRMA (2022), and Viatris programs (2022–2023).

Education and Expertise

• ISTANBUL UNIVERSITY FACULTY OF MEDICINE

Diseases

• Anxiety Disorder
• Bipolar Disorder
• Depression
• Obsessive Compulsive Disorders
• Panic Disorder
• Sematization
• Social Phobia
• Stress Disorder
• Schizophrenia

Treatment Methods

• Cognitive Therapy
• Individual Therapy
• Behavioral Therapy
• EMDR
• Interpersonal therapy
• Psychopharmacological
• Schema therapy

Experience

• Bakirkoy Prof. Dr. Mazhar Osman Mental and Nervous Diseases Training and Research Hospital

Areas of activity: • Research of pathology in gerontological age group (elderly) patients • Clinical nutrition (enteral and parenteral nutrition) • Diabetes mellitus, metabolic syndrome, osteoporosis, thyroid diseases • Arterial hypertension • High body temperature of unknown genesis (fever) • Diseases of the musculoskeletal system, rheumatological diseases • Diseases of the gastrointestinal tract, liver • Disorders of water and electrolyte metabolism, kidney diseases Education: • Higher education - Azerbaijan Medical University, Faculty of General Medicine and Prevention, 2008-2014 • Specialization – Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine Work experience: • Baku State Hospital No. 3, resident physician nephrologist. 2014-2016 • Istanbul Private Bahcelievler Memorial Hospital, specialist in internal medicine. 2021-2022 Research work: (dissertation / defense) • Clinical and laboratory features of patients with acute interstitial nephritis diagnosed during kidney biopsy, factors influencing the etiology and response to treatment. Istanbul University, Istanbul Faculty of Medicine, Department of Nephrology, 2021 Publications:(2) •P343Efficacy of adalimumab mild-to-moderate inflammatory bowel disease: Real-life data from a single-centre experience in the long-term period. January 2020 Journal of Crohns and Colitis DOI: 10.1093/ecco-jcc/jjz203.472 •Concurrent myelomatous pleural effusion and extramedullary mediastinalinvolvement as a relapse manifestation of multiple myeloma. Abstract of the IXth International Eurasian Hematology OncologyCongress17–20October2018Istanbul,Turkey(Concomitant myelomatous pleurisy and extramedullary mediastinal lesion as a recurrent manifestation of multiple myeloma. Abstracts of the IX International Eurasian Oncohematology Congress17–20October2018Istanbul,Türkiye) Memberships in scientific organizations: •Turkish Medical Association

Professor Jair Bar, MD, PhD, is a thoracic oncologist and Deputy Director of the Cancer Center at Sheba Medical Center. He leads the Thoracic Oncology Unit. He treats lung cancer, including advanced non-small cell cases. His care includes medical oncology, radiotherapy, immunotherapy, and targeted therapy.

He runs a translational research lab focused on resistance to immunotherapy. He has published on exhaled-breath cancer metabolism and on angiogenesis inhibition in lung cancer.

He has chaired the Israel Lung Cancer Group since 2003. He is a member of the Israel Society of Clinical Oncology and Radiotherapy, the American Society of Clinical Oncology, and the American Association for Cancer Research. He is board-certified in Medical Oncology and Radiotherapy Oncology. He is a Senior Lecturer at Tel Aviv University.

Dr. Jiri Pazdirek is a board-certified Consultant Physiatrist at Beroun Rehabilitation Hospital. He has over 30 years of experience in rehabilitation and physical medicine. He earned his Medical Doctor degree from Masaryk University. He holds board certifications in Rehabilitation and Physical Medicine (1996) and General Surgery (1989).

Dr. Pazdirek has served as Medical Director and Chief Physiotherapist in leading institutions across Europe and the Middle East. He has played a key role in advancing traumatic brain injury (TBI) rehabilitation. He is the author of several important publications, including a 100-page manual on TBI rehabilitation. He has also delivered many lectures at international conferences. Dr. Pazdirek is accredited by the Czech Medical Chamber and the UK General Medical Council (GMC 6117800).

Naphat Sirinimnualkul, M.D. (Dr. Ken), is a psychiatrist and clinical instructor at the Excellence Center for Sleep Disorders, King Chulalongkorn Memorial Hospital (2022–present). He previously served as a psychiatrist and clinical instructor at the General Police Hospital (Aug–Dec 2021). He completed his psychiatry residency at Chulalongkorn University (2018–2021).

Board/education: Diploma, Board of General Psychiatry, Thai General Medical Council (2018–2021). Graduate Diploma in Clinical Sciences (Psychiatry), Chulalongkorn University (2018–2021). M.D., Second Class Honors, Chulalongkorn University (2011–2017). Training: Cognitive Behavioral Therapy for Insomnia.

Expertise: sleep medicine, neuropsychiatry, consultation-liaison psychiatry, and psychopharmacology. He focuses on the interface between sleep and mood disorders.

Dr. Napassorn Khumchum is a board-certified physiatrist (Diplomate, Thai Board of Rehabilitation Medicine, 2024) at Chonburi Hospital. She provides care in modality, transcranial magnetic stimulation (TMS), and electromyography (EMG) clinics. Her expertise includes neurorehabilitation, stroke recovery, and geriatric rehabilitation. She treats chronic pain and performs ultrasound-guided procedures. She also offers robotic and wearable exoskeleton gait training.

She helps develop and apply advanced rehabilitation technologies. She also serves as a medical lecturer. Her research on the Ipswich Touch Test was presented at the Royal College of Physiatrists Conference 2024. It was published in The Foot (Vol. 61, Dec 2024). Her advanced training includes AOCNR 2023 and courses in spasticity, pain, and ultrasound-guided toxin injection.

Residency: Rehabilitation Medicine, Chulalongkorn University (2024). M.D., Thammasat University (2017). She was an invited speaker at Chonburi Cancer Hospital on swallowing rehabilitation in head and neck cancer patients.